Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 9/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16456347 | 0.83 | KDM4E (0.44) | ALDH1A1KDM4EJAK2JAK3MEN1 | |
| SCHEMBL16456021 | 0.83 | KDM4E (0.44) | ALDH1A1KDM4EJAK2JAK3MEN1 | |
| SCHEMBL16455930 | 0.80 | KDM4E (0.41) | ALDH1A1KDM4EMAPT | |
| SCHEMBL4762286 | 0.79 | TNKS (0.40) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL15204430 | 0.79 | KDM4E (0.42) | ALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL15204431 | 0.79 | KDM4E (0.42) | ALDH1A1KDM4EDDB1CRBN | |
| SCHEMBL830500 | 0.77 | TNKS (0.51) | ALDH1A1 | |
| SCHEMBL8256058 | 0.75 | GPR119 (0.50) | KDM4EPKMDDB1CRBN | |
| SCHEMBL2604347 | 0.73 | TNKS (0.54) | TP53JAK2JAK3 | |
| SCHEMBL30006754 | 0.73 | TNKS (0.54) | TP53JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| US-5760054-A | BENIGN PROSTATIC HYPERTROPHY | MERCK & CO., INC. (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0755392-A4 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0755392-A1 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028397-A1 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | TP53 4818/4885ALDH1A1 1333/4885KDM4E 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.